Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26068495 | 0.80 | ALDH1A1 (0.38) | TSHRALDH1A1 | |
| SCHEMBL9126872 | 0.79 | TSHR (0.42) | TSHRCA12CA1CA2CA9 | |
| SCHEMBL16807253 | 0.77 | TSHR (0.41) | TSHRCA12CA1CA2CA9 | |
| SCHEMBL8970195 | 0.76 | TSHR (0.39) | TSHRCA12CA1CA2CA9 | |
| SCHEMBL54869 | 0.75 | ALDH1A1 (0.48) | TSHRALDH1A1 | |
| SCHEMBL269783 | 0.74 | — | — | |
| SCHEMBL10779482 | 0.74 | NAAA (0.52) | TSHRALDH1A1 | |
| SCHEMBL10820963 | 0.73 | ALDH1A1 (0.46) | TSHRALDH1A1 | |
| SCHEMBL863124 | 0.72 | TSHR (0.43) | TSHRCA12CA1CA2CA9 | |
| SCHEMBL27893088 | 0.72 | ALDH1A1 (0.52) | TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7087614-B2 | Pyrimidine inhibitors of phosphodiesterase (PDE) 7 | BRISTOL-MYERS SQUIBB CO. (US) | 2006-08-08 | — | — | US | disclosed |
| EP-1397142-A4 | PYRIMIDINE INHIBITORS OF PHOSPHODIESTERASE (PDE) 7 | BRISTOL MYERS SQUIBB CO (US) | 2004-11-03 | — | — | EP | disclosed |
| EP-1397142-A2 | PYRIMIDINE INHIBITORS OF PHOSPHODIESTERASE (PDE) 7 | Bristol-Myers Squibb Company (US) | 2004-03-17 | — | — | EP | disclosed |
| US-20030162802-A1 | Pyrimidine inhibitors of phosphodiesterase (PDE) 7 | BRISTOL-MYERS SQUIBB COMPANY | 2003-08-28 | — | — | US | disclosed |
| WO-2002102313-A2 | PYRIMIDINE INHIBITORS OF PHOSPHODIESTERASE (PDE) 7 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162802-A1 | Pyrimidine inhibitors of phosphodiesterase (PDE) 7 | PDE7A, PDE7B, PDE3A | TSHR 3339/4885CA12 4715/4885CA1 3569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.